left space About Us Product Candidates Newsroom Investor Information Business Development

IDDS logo

  Javelin is a specialty pharmaceutical company committed to the development of drugs to treat intense, moderate-to-severe pain
Read more
pixel shim

pixel shim
AMEX :: JAV
pixel shim pixel shim
Quote 1.44
Change 0.00
Date 3/10/2010
Time 4:02pm
Min Delayed Quote
pixel shim

 

2008 Annual Report & Proxy

Click here to download
Javelin's Annual Report for 2008

 

Javelin Pharma's Chinese Microsite

 


News:

March 9, 2010
Javelin Pharmaceuticals Reports Fiscal Results for the Year Ended 2009

February 17, 2010
Javelin Pharmaceuticals' Receives FDA PDUFA Date for
Dyloject™ NDA


February 11, 2010
Third Party Reexamination of Javelin Pharmaceuticals' Phase III Trial Data for Ereska™ (Intranasal Ketamine) Yields Statistically Significant Primary Endpoint


February 2, 2010
FDA Accepts Javelin Pharmaceuticals' Dyloject™ New Drug Application for Formal Review

December 18, 2009
Myriad Pharmaceuticals to Acquire Javelin Pharmaceuticals
Click Here for the Webcast
(Registration Required)

December 2, 2009
Javelin Pharmaceuticals Submits Dyloject™ New Drug Application to FDA for Management of Acute Moderate-to-Severe Pain in Adults

November 10, 2009
Javelin Pharmaceuticals, Inc. Reports Third Quarter 2009 Results

November 4, 2009
Javelin to Announce Third Quarter Results
Click here for the webcast
(Registration Required)




 



 
 

 

CONTACT US   JOIN US   SITE MAP
© 2005-2010 Javelin Pharmaceuticals,Inc. / Intrac,Inc. /IDDS,Inc. All rights reserved. All other trademarks are the properties of their respective owners. Reproduction in whole or in part in any form or medium without express written permission of Javelin Pharmaceuticals,Inc. / Intrac,Inc. /IDDS,Inc. is prohibited.